- Open
- 28.00
- High
- 29.00
- Low
- 27.15
- Close
- 29.00
- Change
- -1.00 (-3.57%)
- Volume
- 4,886
| 6 Oct 2026 | 07:00:03 | COG joins Imperial College-led NHS Study |
| 23 Sept 2026 | 17:10:19 | Director/PDMR Share Purchases |
| 21 Sept 2026 | 07:00:10 | Partnership with C2N and The Alzheimer's Trust |
| 16 Sept 2026 | 07:00:04 | Interim Results |
| 25 Jun 2026 | Annual Report and Accounts (to 2025-12-31) | |
| 1 Jul 2025 | Annual Report and Accounts (to 2024-12-31) | |
| 4 Jul 2024 | Annual Report and Accounts (to 2023-12-31) |
Cambridge Cognition Holdings PLC develops proprietary technologies for cognitive assessment, focusing on brain health. Its primary products include digital touchscreen assessments known as CANTAB® and voice-based assessments, enhanced through the acquisition of Winterlight Labs. The company serves four market segments: Clinical Studies, Academic Research, Healthcare, and Consumer Health & Wellness, with a significant portion of revenue derived from supporting clinical studies for pharmaceutical companies. Cambridge Cognition operates primarily in the healthcare sector, targeting customers in clinical, academic, and consumer markets globally.
| 6 Oct 2026 | 07:00:03 | COG joins Imperial College-led NHS Study |
| 23 Sept 2026 | 17:10:19 | Director/PDMR Share Purchases |
| 21 Sept 2026 | 07:00:10 | Partnership with C2N and The Alzheimer's Trust |
| 16 Sept 2026 | 07:00:04 | Interim Results |
| 25 Jun 2026 | Annual Report and Accounts (to 2025-12-31) | |
| 1 Jul 2025 | Annual Report and Accounts (to 2024-12-31) | |
| 4 Jul 2024 | Annual Report and Accounts (to 2023-12-31) |
Cambridge Cognition Holdings PLC develops proprietary technologies for cognitive assessment, focusing on brain health. Its primary products include digital touchscreen assessments known as CANTAB® and voice-based assessments, enhanced through the acquisition of Winterlight Labs. The company serves four market segments: Clinical Studies, Academic Research, Healthcare, and Consumer Health & Wellness, with a significant portion of revenue derived from supporting clinical studies for pharmaceutical companies. Cambridge Cognition operates primarily in the healthcare sector, targeting customers in clinical, academic, and consumer markets globally.
| 27 Jul 2026 |
| 07:52:18 |
| Trading Update |
| 16 Feb 2026 |
| AIM movers: SkinBioTherapeutics discovers misrepresentation and US contract for Pebble Beach Systems |
| 16 Feb 2026 | Cambridge Cognition shares jump on India deal news |
| 28 Aug 2025 | AIM movers: Potential funding for Tungsten West and ex-dividends |
| 27 Jul 2026 |
| 07:52:18 |
| Trading Update |
| 16 Feb 2026 |
| AIM movers: SkinBioTherapeutics discovers misrepresentation and US contract for Pebble Beach Systems |
| 16 Feb 2026 | Cambridge Cognition shares jump on India deal news |
| 28 Aug 2025 | AIM movers: Potential funding for Tungsten West and ex-dividends |
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £30.21bn | +0.0% | |
| £44m | -0.1% | |
| £16m | -0.3% | |
COGCambridge Cognition Holdings PLC | £12m | -0.2% |
| £6m | -0.5% | |
| £3m | -0.9% |
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £30.21bn | +0.0% | |
| £44m | -0.1% | |
| £16m | -0.3% | |
COGCambridge Cognition Holdings PLC | £12m | -0.2% |
| £6m | -0.5% | |
| £3m | -0.9% |